Zhuo‐Xun Wu

5.2k total citations · 2 hit papers
53 papers, 3.5k citations indexed

About

Zhuo‐Xun Wu is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Zhuo‐Xun Wu has authored 53 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 27 papers in Molecular Biology and 18 papers in Infectious Diseases. Recurrent topics in Zhuo‐Xun Wu's work include Drug Transport and Resistance Mechanisms (32 papers), HIV/AIDS drug development and treatment (16 papers) and Cancer therapeutics and mechanisms (12 papers). Zhuo‐Xun Wu is often cited by papers focused on Drug Transport and Resistance Mechanisms (32 papers), HIV/AIDS drug development and treatment (16 papers) and Cancer therapeutics and mechanisms (12 papers). Zhuo‐Xun Wu collaborates with scholars based in United States, China and Israel. Zhuo‐Xun Wu's co-authors include Zhe‐Sheng Chen, Jing‐Quan Wang, Kejun Hou, Xuan-Yu Chen, Liuya Wei, Jagadish Koya, Chuanxing Xiao, Jilin Li, Dan Zhu and Dongya Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Frontiers in Microbiology.

In The Last Decade

Zhuo‐Xun Wu

53 papers receiving 3.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Microbiota in health and diseases

2022 1.7k citations Zhuo‐Xun Wu, Xuan-Yu Chen et al. Signal Transduction and Targeted Therapy profile →
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies

2023 125 citations Zhenduo Shi, Kun Pang et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhuo‐Xun Wu United States	25	2.1k	836	416	413	367	53	3.5k
Tianyu Liu China	32	2.3k 1.1×	636 0.8×	314 0.8×	508 1.2×	238 0.6×	100	3.4k
Jing‐Quan Wang China	28	2.7k 1.2×	1.4k 1.7×	586 1.4×	425 1.0×	472 1.3×	91	4.5k
Harry Cheuk-Hay Lau Hong Kong	26	2.0k 0.9×	819 1.0×	324 0.8×	485 1.2×	312 0.9×	55	3.3k
Bangmao Wang China	31	1.9k 0.9×	516 0.6×	483 1.2×	484 1.2×	283 0.8×	100	3.4k
Daryl J. Murry United States	38	2.0k 0.9×	885 1.1×	252 0.6×	389 0.9×	389 1.1×	157	4.6k
Yue Ma China	32	1.7k 0.8×	939 1.1×	203 0.5×	223 0.5×	630 1.7×	140	3.7k
Renyuan Gao China	29	3.3k 1.5×	936 1.1×	548 1.3×	784 1.9×	529 1.4×	56	4.4k
Glauben Landskron Chile	10	2.6k 1.2×	799 1.0×	417 1.0×	733 1.8×	393 1.1×	17	4.5k
Rui Zhou China	33	1.5k 0.7×	384 0.5×	284 0.7×	279 0.7×	603 1.6×	176	3.5k
Yali Li China	34	1.3k 0.6×	416 0.5×	201 0.5×	331 0.8×	312 0.9×	161	3.6k

Countries citing papers authored by Zhuo‐Xun Wu

Since Specialization

Citations

This map shows the geographic impact of Zhuo‐Xun Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhuo‐Xun Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhuo‐Xun Wu more than expected).

Fields of papers citing papers by Zhuo‐Xun Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhuo‐Xun Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhuo‐Xun Wu. The network helps show where Zhuo‐Xun Wu may publish in the future.

Co-authorship network of co-authors of Zhuo‐Xun Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhuo‐Xun Wu. A scholar is included among the top collaborators of Zhuo‐Xun Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhuo‐Xun Wu. Zhuo‐Xun Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ge, Minghua, Xuan-Yu Chen, Ping Huang, et al.. (2025). Understanding and overcoming multidrug resistance in cancer. Nature Reviews Clinical Oncology. 22(10). 760–780. 10 indexed citations

Zhang, Meng, Qiu‐Xu Teng, Zi‐Ning Lei, et al.. (2024). Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies. Cancer Letters. 607. 217309–217309. 6 indexed citations

Shi, Zhenduo, Kun Pang, Zhuo‐Xun Wu, et al.. (2023). Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduction and Targeted Therapy. 8(1). 113–113. 125 indexed citations breakdown →

Cai, Chao‐Yun, Zhuo‐Xun Wu, Qiu‐Xu Teng, et al.. (2023). Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitors. Bioorganic Chemistry. 135. 106481–106481. 7 indexed citations

Shi, Zhenduo, Lin Hao, Xiaoxiao Han, et al.. (2022). Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Molecular Cancer. 21(1). 37–37. 77 indexed citations

Pang, Kun, Wei Wang, Jiaxin Qin, et al.. (2022). Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. SHILAP Revista de lepidopterología. 3(4). e175–e175. 74 indexed citations

Wang, Jing‐Quan, Zhuo‐Xun Wu, Yuqi Yang, et al.. (2021). ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates. Journal of Evidence-Based Medicine. 14(3). 232–256. 105 indexed citations

James, Alva Rani, et al.. (2021). Long noncoding RNAs have pivotal roles in chemoresistance of acute myeloid leukemia. Drug Discovery Today. 26(7). 1735–1743. 23 indexed citations

Lei, Zi‐Ning, Qiu‐Xu Teng, Zhuo‐Xun Wu, et al.. (2021). Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. SHILAP Revista de lepidopterología. 2(4). 765–777. 36 indexed citations

10.

Wu, Zhuo‐Xun, Yuqi Yang, Jing‐Quan Wang, et al.. (2021). Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. Biomedicine & Pharmacotherapy. 136. 111223–111223. 17 indexed citations

11.

Narayanan, Silpa, Jing‐Quan Wang, Zhuo‐Xun Wu, et al.. (2021). The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. International Journal of Molecular Sciences. 22(5). 2463–2463. 13 indexed citations

12.

Patel, Harsh, Zhuo‐Xun Wu, Yanglu Chen, Letao Bo, & Zhe‐Sheng Chen. (2021). Drug resistance: from bacteria to cancer. Molecular Biomedicine. 2(1). 26 indexed citations

13.

Wu, Zhuo‐Xun, Qiu‐Xu Teng, Yuqi Yang, et al.. (2021). MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study. Acta Pharmaceutica Sinica B. 12(5). 2609–2618. 16 indexed citations

14.

Yang, Yuqi, Ning Ji, Chao‐Yun Cai, et al.. (2020). Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Communications. 40(7). 285–300. 31 indexed citations

15.

Wu, Zhuo‐Xun, Yuqi Yang, Guangsuo Wang, et al.. (2020). Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells. Cancer Science. 111(8). 2872–2882. 28 indexed citations

16.

Song, Huibin, Dongcheng Liu, Shaowei Dong, et al.. (2020). Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduction and Targeted Therapy. 5(1). 193–193. 96 indexed citations

17.

Wu, Zhuo‐Xun, Yuqi Yang, Qiu‐Xu Teng, et al.. (2020). Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers. 12(1). 186–186. 38 indexed citations

18.

Wang, Jingqiu, Dong‐Hua Yang, Yuqi Yang, et al.. (2020). Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. International Journal of Molecular Sciences. 21(4). 1387–1387. 33 indexed citations

19.

Zhang, Lei, Yidong Li, Qianchao Wang, et al.. (2020). The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Molecular Cancer. 19(1). 10–10. 101 indexed citations

20.

Wu, Zhuo‐Xun, Qiu‐Xu Teng, Chao‐Yun Cai, et al.. (2019). Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochemical Pharmacology. 166. 120–127. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact